IgA nephropathy, or Berger's disease is a condition brought on by immunoglobulin A (IgA) buildup in the kidneys' filtering units, or glomeruli. Over time, inflammation brought on by this accumulation may impede renal function. Although the precise etiology is uncertain, infections or genetic factors may be involved. Swelling, proteinuria, and blood in the urine are common symptoms. It can develop into renal failure if treatment is not received. Symptom management, blood pressure control, and perhaps immunosuppressive medicine are all part of the treatment. The rising number of cases is anticipated to impact the pipeline landscape for IgA nephropathy emerging drugs positively.
The IgA Nephropathy Drug Pipeline Insight Report by Expert Market Research gives comprehensive insights into IgA nephropathy therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for IgA nephropathy. The IgA nephropathy report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The IgA nephropathy pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on patients suffering from the condition, and alignment with IgA nephropathy treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to IgA Nephropathy.
When immunoglobulin A (IgA) is inappropriately deposited in the glomeruli, it triggers an inflammatory response that results in IgA nephropathy. IgA and other proteins produce immune complexes that activate complement and attract inflammatory cells, causing damage to kidney tissue. Reduced filtration, glomerular damage, and the development of chronic kidney disease are the outcomes of this. Repeated inflammation over time can cause kidney failure, fibrosis, and scarring.
IgA Nephropathy therapeutics include telitacicept, atrasentan, among others. The use of monoclonal antibodies to treat IgA nephropathy is being investigated. To lessen inflammation and stop additional kidney injury, these antibodies target particular immunological pathways, such as those involving B cells or the complement system. Monoclonal antibody treatments, such as those that target complement or CD20, are being researched to help individuals with IgA nephropathy. Further, the rising focus on the development of IgA Nephropathy emerging drugs and the advances in the understanding of the molecular pathogenesis of the disease are expected to support the pipeline expansion in the coming years.
IgA nephropathy is thought to affect 2.5 out of every 100,000 people worldwide, with higher rates seen in East Asia, where it may be the cause of up to 40% of kidney biopsies. Due to variations in diagnosis procedures and population composition, the prevalence is lower in North America (10%) and Europe (20–30%). The male-to-female ratio ranges from 2:1 to 6:1, with males being the condition's primary victims.
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for IgA nephropathy. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of IgA nephropathy drug candidates.
By Phase
By Drug Class
By Route of Administration
The report covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II and III cover a major share of the total clinical trials, with a substantial number of IgA Nephropathy drugs undergoing clinical development.
The drug molecule categories covered under IgA nephropathy pipeline analysis include small molecules, monoclonal antibodies and peptides among others. The IgA nephropathy report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for IgA nephropathy.
The EMR report for the IgA nephropathy drug pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed IgA nephropathy therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in IgA nephropathy clinical trials:
Major drugs currently in the drug pipeline are as follows:
Sponsored by RemeGen Co., Ltd., the objective of this multicenter clinical trial is to investigate the efficacy and safety of the IgA nephropathy drug candidate, Telitacicept in the affected patients. The study is under Phase III clinical development and has an estimated 90 participants.
Chinook Therapeutics is conducting a Phase III study aimed at examining the efficacy of the investigational drug atrasentan for the treatment of IgA nephropathy. The interventional study has enrolled about 320 subjects with patients with biopsy-proven IgAN.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
The IgA Nephropathy Drug Report provides a strategic overview of the latest and future landscape of treatments for IgA Nephropathy. it provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into market trends, regulatory environments, and potential growth opportunities within IgA nephropathy pipeline insights.
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
United States
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
Share